Heparin calcium is calcium salt form of heparin. Heparin calcium is a negatively charged linear polysaccharide that belongs to the glycosaminoglycan family. Ðeparin is an anticoagulant which is indicated for the prevention and treatment of thrombotic events such as pulmonary embolism, deep vein thrombosis and atrial fibrillation. As a glycosaminoglycan anticoagulant, heparin calcium binds to antithrombin III to form a heparin-antithrombin III complex. Heparin is also used to prevent excess coagulation during cardiac surgery, dialysis, and others. Heparin can be administered by intravenous or subcutaneous route. Unfractionated heparin and low molecular weight heparin are the two forms of calcium heparin. Subcutaneous heparin is administred to prevent thromboembolism and the administration of intravenous heparin is used for therapeutic anticoagulation. Bleeding, thrombocytopenia, injection site reactions, and other adverse effects are seen with chronic heparin administration. Bleeding is a major complication associated with heparin use. In long term use, unfractionated heparin has a higher risk of osteoporosis. Unfractionated heparin is more specific than low molecular weight heparin for thrombin and the effects of unfractionated heparin can typically be reversed by using protamine sulfate.
Market Dynamics
Increasing adoption of inorganic strategies such as launch of campaign, in order to raise awareness is expected to drive the global heparin calcium market growth over the forecast period. For instance, in November 2020, The Bristol Myers Squibb–Pfizer Alliance, announced that they had launched the ‘No Time to Wait’ awareness campaign, to raise awareness of the symptoms of deep vein thrombosis. This campaign helps people to find additional information about deep vein thrombosis.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook